SG11202004833SA - IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS - Google Patents

IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Info

Publication number
SG11202004833SA
SG11202004833SA SG11202004833SA SG11202004833SA SG11202004833SA SG 11202004833S A SG11202004833S A SG 11202004833SA SG 11202004833S A SG11202004833S A SG 11202004833SA SG 11202004833S A SG11202004833S A SG 11202004833SA SG 11202004833S A SG11202004833S A SG 11202004833SA
Authority
SG
Singapore
Prior art keywords
immunotherapies
effector cells
ipsc derived
derived effector
enhanced
Prior art date
Application number
SG11202004833SA
Inventor
Bahram Valamehr
Ryan Bjordahl
Tom Lee
Svetlana Gaidarova
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of SG11202004833SA publication Critical patent/SG11202004833SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG11202004833SA 2017-12-08 2018-11-30 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS SG11202004833SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762596659P 2017-12-08 2017-12-08
US201862657626P 2018-04-13 2018-04-13
PCT/US2018/063362 WO2019112899A2 (en) 2017-12-08 2018-11-30 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Publications (1)

Publication Number Publication Date
SG11202004833SA true SG11202004833SA (en) 2020-06-29

Family

ID=66749947

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004833SA SG11202004833SA (en) 2017-12-08 2018-11-30 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Country Status (12)

Country Link
US (1) US20210015859A1 (en)
EP (1) EP3720946A4 (en)
JP (2) JP2021505131A (en)
KR (1) KR20200097749A (en)
CN (1) CN111556892A (en)
AU (1) AU2018381191A1 (en)
BR (1) BR112020010597A2 (en)
CA (1) CA3083109A1 (en)
IL (1) IL275180A (en)
MX (1) MX2020005477A (en)
SG (1) SG11202004833SA (en)
WO (1) WO2019112899A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728563A4 (en) * 2017-12-22 2021-11-10 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
EP3924467A1 (en) * 2019-02-15 2021-12-22 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy
US20220184142A1 (en) * 2019-04-11 2022-06-16 Fate Therapeutics, Inc. CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS
CN114286683A (en) * 2019-07-17 2022-04-05 新加坡国立大学 Functional conjugates synthesized and secreted by immune cells
WO2021011919A1 (en) * 2019-07-17 2021-01-21 Fate Therapeutics, Inc. Immune effector cell engineering and use thereof
EP4034638A2 (en) * 2019-09-25 2022-08-03 Fate Therapeutics, Inc. Multi-targeting effector cells and use thereof
WO2021071962A1 (en) * 2019-10-07 2021-04-15 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
WO2021077117A1 (en) * 2019-10-17 2021-04-22 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
CN111269326A (en) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 Novel chimeric antigen receptor and use thereof
AU2021292695A1 (en) * 2020-06-19 2023-02-02 Fate Therapeutics, Inc. Combining iPSC-derived effector cell types for immunotherapy use
WO2022007796A1 (en) * 2020-07-06 2022-01-13 上海鑫湾生物科技有限公司 Immune cell co-expressing il-21 and hrcd16 chimeric receptor, and application thereof
EP4185616A1 (en) * 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
CN114276996A (en) * 2020-09-28 2022-04-05 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell derivative expressing PD-1/PD-L1 blocking substance and application
EP4237004A1 (en) * 2020-10-28 2023-09-06 SRI International Genetically engineered antigen-specific natural killer cells for in situ synthesis of proteins
CN114426953A (en) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell derivative for expressing IL-12 and application thereof
CN114457025A (en) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing BTLA blocking substance or derivative thereof and application
CN114457028A (en) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing CD38 antibody, derivative and application thereof
CN114457022A (en) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing OX40 activated antibody and derivative and application thereof
CN114525258A (en) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing PCSK9 blocker or derivative thereof and application
CN114457031A (en) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing B7-H5 blocking substance or derivative thereof and application
EP4240830A1 (en) * 2020-11-03 2023-09-13 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
CN114525259A (en) * 2020-11-03 2022-05-24 南京北恒生物科技有限公司 Chimeric antigen receptor targeting CD7 and uses thereof
EP4240832A1 (en) * 2020-11-04 2023-09-13 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
JP2023548467A (en) * 2020-11-04 2023-11-17 フェイト セラピューティクス，インコーポレイティド Engineered iPSCs and persistent immune effector cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN114645018A (en) * 2020-12-18 2022-06-21 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing CD38 targeted inhibitory factor, derivative and application thereof
TW202241935A (en) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 Chimeric antigen receptor system with adaptable receptor specificity
CN114645020A (en) * 2020-12-21 2022-06-21 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing targeted NR4A1 inhibitory factor, and derivative and application thereof
CN114657135A (en) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing Tim-3 targeted inhibitory factor, derivative and application thereof
US20220193134A1 (en) * 2020-12-23 2022-06-23 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
JP2024503290A (en) 2020-12-31 2024-01-25 クリスパー セラピューティクス アクチェンゲゼルシャフト universal donor cells
CA3204417A1 (en) * 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
BR112023018844A2 (en) * 2021-04-07 2023-10-10 Century Therapeutics Inc COMPOSITIONS AND METHODS FOR GENERATION OF GAMMA-DELTA T CELLS FROM INDUCED PLURIPOTENT STEM CELLS
IL308097A (en) * 2021-05-27 2023-12-01 Sana Biotechnology Inc Hypoimmunogenic cells comprising engineered hla-e or hla-g
US20230014010A1 (en) * 2021-06-23 2023-01-19 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
WO2023019185A1 (en) * 2021-08-10 2023-02-16 Gentibio, Inc. Compositions and methods for engineering stable tregs
CN114107378A (en) * 2021-09-13 2022-03-01 钦元再生医学(珠海)有限公司 Preparation method of universal CAR-T cell
WO2023081896A1 (en) * 2021-11-08 2023-05-11 Fate Therapeutics, Inc. Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
CN116103239A (en) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
CN114414541A (en) * 2021-12-17 2022-04-29 上海药明生物医药有限公司 Method for detecting killing effect of T cells by applying 3D cell imaging analysis system
WO2023116929A1 (en) * 2021-12-24 2023-06-29 Hemacell Therapeutics Inc. Method for producing human induced pluripotent stem cells through homologous recombination and integrase-mediated recombination
CN114317607A (en) * 2021-12-31 2022-04-12 西安桑尼赛尔生物医药有限公司 Double-target universal CAR-T cell fusing primary targeting CD7CAR and secondary targeting BCMA and preparation method thereof
WO2023182861A1 (en) * 2022-03-25 2023-09-28 에이치케이이노엔 주식회사 Anti-hla-g chimeric antigen receptor, and use thereof
JP2024515920A (en) * 2022-04-08 2024-04-11 フェイト セラピューティクス，インコーポレイティド Cells bearing solid tumor targeting scaffolds and uses thereof
CN114478806B (en) * 2022-04-14 2022-07-01 呈诺再生医学科技(北京)有限公司 Chimeric receptor for improving killing activity of immune cells and application thereof
WO2023240248A2 (en) 2022-06-09 2023-12-14 Umoja Biopharma, Inc. Compositions and methods for nk cell differentiation
EP4299734A1 (en) * 2022-07-01 2024-01-03 ETH Zurich Cell line for discovering tcr antigens and uses thereof
WO2024026391A1 (en) 2022-07-27 2024-02-01 Umoja Biopharma, Inc. Differentiation of stem cells in suspension culture
CN116042527B (en) * 2022-09-07 2023-08-22 广州瑞臻再生医学科技有限公司 iPS cell line for promoting NK cell differentiation and construction method and application thereof
CN116445414A (en) * 2023-03-03 2023-07-18 广州瑞臻再生医学科技有限公司 Method for genetically modifying pluripotent stem cell-derived enhanced NK cells and application thereof
CN116410336B (en) * 2023-06-02 2023-09-22 云南赛元生物技术有限公司 Chimeric antigen receptor encoding nucleotide, CAR-NK cell, construction method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
DK2981607T3 (en) * 2013-04-03 2020-11-16 Memorial Sloan Kettering Cancer Center EFFICIENT GENERATION OF TUMOR-TARGETED T-CELLS DERIVED FROM PLURIPOTENT STEM CELLS
JP2018522833A (en) * 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Chimeric antigen receptor (CAR) constructs and disease treatment with T cells (CAR-T) or NK cells (CAR-NK) expressing CAR constructs
JP2018532729A (en) * 2015-09-25 2018-11-08 アルター・バイオサイエンス・コーポレーション Interleukin-15 superagonist significantly enhances graft versus tumor activity
ES2953925T3 (en) * 2015-11-04 2023-11-17 Fate Therapeutics Inc Genomic engineering of pluripotent cells
JP2019502725A (en) * 2016-01-20 2019-01-31 フェイト セラピューティクス，インコーポレイテッド Compositions and methods for immune cell regulation in adoptive immunotherapy

Also Published As

Publication number Publication date
US20210015859A1 (en) 2021-01-21
WO2019112899A8 (en) 2019-08-22
KR20200097749A (en) 2020-08-19
EP3720946A2 (en) 2020-10-14
EP3720946A4 (en) 2021-08-18
JP2024020364A (en) 2024-02-14
CN111556892A (en) 2020-08-18
WO2019112899A2 (en) 2019-06-13
BR112020010597A2 (en) 2020-10-27
JP2021505131A (en) 2021-02-18
WO2019112899A3 (en) 2019-07-18
AU2018381191A1 (en) 2020-06-04
MX2020005477A (en) 2020-11-06
IL275180A (en) 2020-07-30
CA3083109A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
IL275180A (en) Immunotherapies using enhanced ipsc derived effector cells
IL283607A (en) Immunotherapies using enhanced ipsc derived effector cells
GB201621889D0 (en) Cell
GB201610515D0 (en) Cell
IL273915A (en) Cell
PL3451416T3 (en) Second battery
GB2553537B (en) Battery box
GB201616238D0 (en) Modified T cells
IL269168A (en) Single cell analysis
GB201713078D0 (en) T Cell Modification
GB201707783D0 (en) Cell
GB201603372D0 (en) Cell
GB201707779D0 (en) Cell
AP01012S1 (en) Battery
GB201609539D0 (en) Battery arrangement
GB201720949D0 (en) Cell
HK1256933A1 (en) Battery
GB201718697D0 (en) Cell
ZA201900891B (en) B-cell-mimetic cells
GB201609604D0 (en) Cell
GB201621878D0 (en) Battery
GB201617716D0 (en) Cell
GB201607461D0 (en) Battery
GB201717713D0 (en) Battery
GB201714718D0 (en) Cell